Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow Quality Index
Tianjin Lisheng Pharmaceutical Co Ltd cash flow quality index. Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Cash Flow Quality Index of 6.32x as of December 2025. Operating cash flow of CN¥287.81 Million exceeds net income of CN¥45.54 Million, indicating high earnings quality where cash backs reported profits. See 002393 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Cash flow quality index of Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2025. Historical Cash Flow Quality Index for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Tianjin Lisheng Pharmaceutical Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow Quality Index by Year (2007–2025)
Tianjin Lisheng Pharmaceutical Co Ltd cash flow quality index by year from 2007 to 2025. Year-by-year earnings quality comparison for Tianjin Lisheng Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see how efficiently does Tianjin Lisheng Pharmaceutical Co Ltd generate cash.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.09x | CN¥451.85 Million | CN¥416.28 Million | ▲ +126.9% |
| 2024 | 0.48x | CN¥88.26 Million | CN¥184.53 Million | ▼ -17.4% |
| 2023 | 0.58x | CN¥209.51 Million | CN¥361.83 Million | ▼ -83.6% |
| 2022 | 3.54x | CN¥331.38 Million | CN¥93.61 Million | ▲ +120.2% |
| 2021 | 1.61x | CN¥196.34 Million | CN¥122.11 Million | ▼ -81.9% |
| 2020 | 8.86x | CN¥76.37 Million | CN¥8.62 Million | ▲ +521.5% |
| 2019 | 1.43x | CN¥268.33 Million | CN¥188.14 Million | ▲ +62.2% |
| 2018 | 0.88x | CN¥162.69 Million | CN¥184.98 Million | ▼ -42.7% |
| 2017 | 1.53x | CN¥179.25 Million | CN¥116.82 Million | ▲ +2.2% |
| 2016 | 1.50x | CN¥173.60 Million | CN¥115.61 Million | ▼ -13.4% |
| 2015 | 1.73x | CN¥198.13 Million | CN¥114.22 Million | ▲ +123.0% |
| 2014 | 0.78x | CN¥72.24 Million | CN¥92.89 Million | ▼ -20.0% |
| 2013 | 0.97x | CN¥289.62 Million | CN¥298.06 Million | ▲ +16.9% |
| 2012 | 0.83x | CN¥250.72 Million | CN¥301.74 Million | ▲ +105.8% |
| 2011 | 0.40x | CN¥134.58 Million | CN¥333.39 Million | ▼ -52.6% |
| 2010 | 0.85x | CN¥186.55 Million | CN¥219.26 Million | ▼ -27.9% |
| 2009 | 1.18x | CN¥196.14 Million | CN¥166.25 Million | ▲ +33.7% |
| 2008 | 0.88x | CN¥126.59 Million | CN¥143.46 Million | ▼ -33.4% |
| 2007 | 1.33x | CN¥174.94 Million | CN¥131.95 Million | — |